New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Egypt is expanding its Universal Health Insurance System to ensure that all citizens have health coverage by 2030 ...

One patient in the risankizumab group and two in the placebo ... for this study and provided writing support for this manuscript. Medical writing assistance, funded by AbbVie, was provided by Lisa M ...

The study is limited by self-reported patient responses that were not ... who opted to receive communications. Financial assistance in developing the survey and collecting data was provided by AbbVie.

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

Patient assistance programs (PAPs) emerged to help patients who lack health insurance or prescription drug coverage obtain ...

AbbVie's success with Humira is a textbook example. Humira (adalimumab) is an immunosuppressant drug used to treat several autoimmune diseases, in which a patient's immune system attacks healthy ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.

Additionally, there are programmes with counsellors who work with the patients to determine alternative ways to reduce a patient's cost, such as co-pay assistance, prescription saving programmes ...

On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...